In this July 10, 2006 file photo, Genentech researcher Mark Nagel works on an experiment in a research laboratory at Genentech headquarters in a South San Francisco, Calif. Swiss pharmaceutical giant Roche agreed to pay $46.8 billion to buy the 44 percent of biotech pioneer Genentech that it doesn't already own, ending a long corporate struggle with its U.S.-based cancer drug partner.